GlassScriptPhysician profile
Jianwen Wu
NPI 1154381218
$2,795.96
in general payments reported to CMS, 2019-2025
36 companies · $584 in 2025
The $584 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $85.91 · 2021: $178 · 2022: $224 · 2023: $491 · 2024: $551 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.81 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $374.25 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $346.04 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $323.61 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.58 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $223.89 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $204.26 | 2019-2025 | |
| Sanofi Pasteur INC. | $108.43 | 2019-2023 | |
| Abbvie INC. | $102.57 | 2019-2023 | Ubrelvy |
| Merck Sharp & Dohme LLC | $91.18 | 2021-2025 | Capvaxive, Gardasil 9, Recombivax Hb |
| Glaxosmithkline, LLC. | $76.88 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $71.21 | 2019 | |
| Abbott Laboratories | $50.28 | 2023-2025 | Prodigy, Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $43.78 | 2022-2023 | |
| Almatica Pharma LLC | $38.31 | 2023 | Loreev Xr |
| Allergan, INC. | $37.70 | 2019-2020 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jianwen Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.